EUSA Pharma
Manufacturing · United Kingdom · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Breakspear Park Breakspear Way Ground Fl...Phone Number
+44 3305001140Website
www.eusapharma.comRevenue
$67.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About EUSA Pharma
Founded in 1985, EUSA Pharma is a pharmaceutical company focused on oncology and rare disease. EUSA Pharma is located in the United KingdomExplore more
EUSA Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EUSA Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once EUSA Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at EUSA Pharma
Website visits: Recent activity has been detected on your website
Click to see if EUSA Pharma had a recent Job posting/layoffs
EUSA Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on EUSA Pharma recently announced quarterly report
Product Launch: Get notified when EUSA Pharma launches new products
Check out if EUSA Pharma is spiking on competitors!
Check if EUSA Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined EUSA Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to EUSA Pharma
Compare insights from companies similar to EUSA Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
EUSA Pharma
$67.5M
201-500
Private
-
1985
DW
DeWayne WilcherRegional Director, Business & Key Account Manager
$213.6M
51-200
Public
$1.1B
1991
SK
Stephen KetchumExecutive VP & President, Research & Development & Chief Scientific Officer
Company Profile Activity
Activity Insights
EUSA Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EUSA Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EUSA Pharma.
EUSA Pharma Tech Stack
A closer look at the technologies used by EUSA Pharma
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
EUSA Pharma is planning to move offices in April 2024. The move will impact approximately 2049 employees at the existing office located at 300 Barr Harbor Dr, Conshohocken, PA.
Facilities Relocation/Expansion
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
EUSA Pharma News & Media
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
CAMBRIDGE, Mass. & BEIJING & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has granted QARZIBA® (dinutuximab beta) conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative tSYLVANT® (siltuximab) Recommended by the National Comprehensive Cancer Network® (NCCN®) as the Preferred Treatment Option for Patients with Idiopathic Multicentric Castleman Disease (iMCD) regardless of histopathologic subtype
HEMEL HEMPSTEAD, England & BURLINGTON, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited (“EUSA Pharma”), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensive Cancer Network® (NCCN®) has updated their Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas to include siltuximab (SYLVANT®) as the preferred primary treatment for patients with human immunodeficiency virus–negative [HIV(-)] and human herpesvirusEUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China
HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT® (siltuximab for injection) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Siltuximab is a monoclonal antibody approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) for the treatment of aEUSA Pharma annonce le recrutement du premier patient dans un essai clinique randomisé de Phase 3 portant sur le siltuximab chez des patients hospitalisés atteints de COVID-19 ou d'un autre syndrome de détresse respiratoire aiguë (SDRA) associé à...
HEMEL HEMPSTEAD, Royaume-Uni & BURLINGTON, Massachusetts--(BUSINESS WIRE)-- EUSA Pharma annonce le recrutement du premier patient dans un essai clinique randomisé de Phase 3 portant sur le siltuximab chez des patients hospitalisés atteints de COVID-19 ou d'un autre syndrome de détresse respiratoire aiguë (SDRA) associé à une infection respiratoire virale EUSA Pharma (UK) Limited ("EUSA Pharma"), une société biopharmaceutique mondiale, a annoncé aujourd'hui le recrutement d'un premier patient d
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding EUSA Pharma
Sign Up For FreeTo access detailed company insights
Founded in 1985, EUSA Pharma is a pharmaceutical company focused on oncology and rare disease. EUSA Pharma is located in the United Kingdom... Read More
